This Article Order Full text via Infotrieve Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Zhang, H. Articles by Archard, L. C. Search for Related Content PubMed PubMed Citation Articles by Zhang, H. Articles by Archard, L. C.

American Journal of Pathology, Vol 150, 2197-2207, Copyright © 1997 by American Society for Investigative Pathology

REGULAR ARTICLES

Coxsackievirus B3-induced myocarditis. Characterization of stable attenuated variants that protect against infection with the cardiovirulent wild-type strain

H Zhang, P Morgan-Capner, N Latif, YA Pandolfino, W Fan, MJ Dunn and LC Archard
Department of Biochemistry, Charing Cross and Westminster Medical School, University of London, United Kingdom.

Coxsackievirus B3 (CVB3) is the enterovirus most frequently involved in human myocarditis or dilated cardiomyopathy. Attenuated variants were derived from a cardiovirulent CVB3 reactivated from a sequenced, full- length cDNA clone. The prophylactic potential of these variants was assessed in SWR/Ola (H-2q) mice. Animals immunized with attenuated variants of CVB3 were protected from myocarditis when challenged subsequently with the cardiovirulent wild-type virus. In contrast to nonimmunized controls, the wild-type virus was not isolated from myocardium of protected mice, nor was viral RNA detected in myocardium by reverse transcription nested polymerase chain reaction. Specific antibody to CVB3 was demonstrated by virus neutralization assay and by indirect immunofluorescence. The attenuated phenotype of one variant, p14V-1, remained stable throughout 20 consecutive passages in SWR mice and induced a markedly lower level of autoantibody against mouse cardiac myosin heavy chain than the cardiovirulent wild type. These data demonstrate that attenuated strains protect against CVB3-induced myocarditis in mice, that the attenuated phenotype is stable, and that they do not persist in myocardium nor induce a significant level of anti-heart anti-body against myosin heavy chain. These attenuants may be the basis of a live vaccine against CVB3 in the prevention of enteroviral heart muscle disease.

This article has been cited by other articles:

				T. Peng, Y. Li, Y. Yang, C. Niu, P. Morgan-Capner, L. C. Archard, and H. Zhang Characterization of Enterovirus Isolates from Patients with Heart Muscle Disease in a Selenium-Deficient Area of China J. Clin. Microbiol., October 1, 2000; 38(10): 3538 - 3543. [Abstract] [Full Text]